Post by Gil Morgan

This week's OncoAlert Newsletter is NOW out 🚨 A landmark week in oncology — CAR T-cells in a solid tumor for the first time in a randomized trial, a new EC approval in triple-negative breast cancer, and practice-changing data across GU, lung, breast, and GI cancers. Highlights this week: 🔬 CAR T-cell therapy (satri-cel) beats physician's choice in gastric cancer — the first positive randomized CAR T trial in a solid tumor (The Lancet) 🔬 EC approves sacituzumab govitecan for 1L mTNBC not eligible for immunotherapy — based on ASCENT-03 (Gilead) 🔬 Ivonescimab + chemo improves OS after EGFR-TKI failure in NSCLC — HARMONi-A in JAMA 🔬 Palbociclib + ET outperforms chemotherapy in high-risk HR+/HER2- MBC — PADMA phase IV (ESMO Open) 🔬 GLP-1 agonists associated with significantly lower breast cancer incidence in overweight women (JCO Oncology Practice) 🔬 Triplet therapy advantage in high-volume bone metastatic prostate cancer — ARON-3 (European Urology Oncology) 🔬 EC approves encorafenib + cetuximab + FOLFOX in BRAFV600E mCRC — 51% reduction in mortality risk (BREAKWATER) Plus lung cancer, radiation oncology, immunotherapy, and more. 📩 Not subscribed yet? Join 9,000+ oncology professionals → https://buff.ly/25YHTzM #oncology #breastcancer #lungcancer #ProstateCancer #BladderCancer #RadOnc https://lnkd.in/eyAQsEux